The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

  1. Christine Trumpfheller*,
  2. Marina Caskey*,
  3. Godwin Nchinda*,
  4. Maria Paula Longhi*,
  5. Olga Mizenina*,
  6. Yaoxing Huang,
  7. Sarah J. Schlesinger*,,
  8. Marco Colonna, and
  9. Ralph M. Steinman*,§
  1. *Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, 1230 York Avenue, New York, NY 10065;
  2. The Aaron Diamond AIDS Research Center, 455 First Avenue, New York, NY 10016; and
  3. Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St. Louis, MO 63110
  1. Contributed by Ralph M. Steinman, December 20, 2007 (received for review November 27, 2007)

Abstract

CD4+ Th1 type immunity is implicated in resistance to global infectious diseases. To improve the efficacy of T cell immunity induced by human immunodeficiency virus (HIV) vaccines, we are developing a protein-based approach that directly harnesses the function of dendritic cells (DCs) in intact lymphoid tissues. Vaccine proteins are selectively delivered to DCs by antibodies to DEC-205/CD205, a receptor for antigen presentation. We find that polyriboinosinic:polyribocytidylic acid (poly IC) independently serves as an adjuvant to allow a DC-targeted protein to induce protective CD4+ T cell responses at a mucosal surface, the airway. After two doses of DEC-targeted, HIV gag p24 along with poly IC, responder CD4+ T cells have qualitative features that have been correlated with protective function. The T cells simultaneously make IFN-γ, tumor necrosis factor (TNF)-α, and IL-2, and in high amounts for prolonged periods. The T cells also proliferate and continue to secrete IFN-γ in response to HIV gag p24. The adjuvant role of poly IC requires Toll-like receptor (TLR) 3 and melanoma differentiation-associated gene-5 (MDA5) receptors, but its analog poly IC12U requires only TLR3. We suggest that poly IC be tested as an adjuvant with DC-targeted vaccines to induce numerous multifunctional CD4+ Th1 cells with proliferative capacity.

Footnotes

  • §To whom correspondence should be addressed. E-mail: steinma{at}mail.rockefeller.edu
  • Author contributions: C.T., M. Caskey, G.N., M.P.L., and R.M.S. designed research; C.T., M. Caskey, G.N., M.P.L., and O.M. performed research; Y.H., S.J.S., and M. Colonna contributed new reagents/analytic tools; C.T., M. Caskey, G.N., M.P.L., O.M., Y.H., S.J.S., and R.M.S. analyzed data; and C.T. and R.M.S. wrote the paper.

  • Conflict of interest statement: R.M.S. is a consultant to Celldex, which is developing human DEC-205-based vaccines. All other authors declare no conflict of interest.

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0711976105/DC1.

« Previous | Next Article »Table of Contents